Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sionna Therapeutics (Nasdaq: SION) announced management will present at the 44th Annual J.P.

Rhea-AI Summary

Sionna Therapeutics (Nasdaq: SION) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 9:45 a.m. PT / 12:45 p.m. ET. The company is a clinical-stage biopharmaceutical focused on developing medicines to normalize CFTR function for cystic fibrosis.

A live webcast of the presentation will be available on the company’s Investors > Events page at https://investors.sionnatx.com/, and a replay will be posted after the event.

Argus Jan 5 session

+4.18% close to close Open Argus

Details

News Market Reaction – SION

On Jan 5, the day this news came out, SION closed 4.18% above the previous close.

Data tracked by StockTitan Argus for the Jan 5 session.

Market Context

This announcement highlights Sionna’s participation at the 44th Annual J.P. Morgan Healthcare Confer...

Analysis

This announcement highlights Sionna’s participation at the 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026, providing a platform to showcase its CFTR‑focused pipeline. Recent history includes initiation of the PreciSION CF Phase 2a trial and strong liquidity of $325.0M reported in Q3 2025. Investors tracking the story may focus on upcoming mid‑2026 clinical readouts and ongoing regulatory filings and insider activity as key future reference points.

Key Figures

Presentation time: 9:45 a.m. PT / 12:45 p.m. ET

Presentation time

9:45 a.m. PT / 12:45 p.m. ET

J.P. Morgan Healthcare Conference on Jan 13, 2026

Historical Context

5 past events · Latest: Nov 24

5 events

1. Nov 24

   Investor conferences

   24h Move

   +1.6%

   Management participation in early December 2025 healthcare investor conferences.

2. Nov 05

   Earnings and pipeline

   24h Move

   -1.6%

   Q3 2025 results, strong cash position, and advancement of SION‑719 and SION‑451.

3. Nov 04

   Investor conferences

   24h Move

   -1.2%

   Planned fireside chats at November 2025 healthcare conferences with webcast access.

4. Oct 24

   Clinical data update

   24h Move

   -1.0%

   Phase 1 and preclinical data on NBD1 stabilizers SION‑719 and SION‑451 in CF.

5. Oct 21

   Clinical trial start

   24h Move

   +32.0%

   Initiation of PreciSION CF Phase 2a trial adding SION‑719 to standard of care.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cystic fibrosis, cystic fibrosis transmembrane conductance regulator (cftr) protein

2 terms

cystic fibrosis medical

"on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF)"

A genetic disease that causes the body to produce thick, sticky mucus that clogs airways and digestive passages, leading to ongoing lung infections, breathing difficulty, and problems absorbing nutrients. For investors, cystic fibrosis matters because treatments range from symptom management to pricey, targeted drugs that can change patient outcomes; progress in therapies, clinical trial results, regulatory approvals, and reimbursement decisions can significantly affect the commercial value of companies working in this area.

cystic fibrosis transmembrane conductance regulator (cftr) protein medical

"medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein"

A protein that functions like a tiny faucet on cell surfaces, controlling the flow of salt and water in and out of many tissues; when the CFTR protein doesn't work properly because of genetic mutations, thick mucus and organ damage can result. For investors, CFTR is a clear drug-development and diagnostic target: therapies that restore or compensate for its function can transform patient outcomes and drive meaningful market value in biotech and pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 44^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13^th, 2026 at 9:45 a.m. PT/12:45 p.m. ET.

A live webcast of the presentation will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will also be available following the event.

About Sionna Therapeutics 
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.

Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact 
Adam Daley 
CG Life 
212.253.8881 
adaley@cglife.com

Investor Contact 
Juliet Labadorf 
ir@sionnatx.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Sionna Therapeutics (SION) present at the J.P. Morgan Healthcare Conference?

Sionna will present on January 13, 2026 at 9:45 a.m. PT / 12:45 p.m. ET.

Where can investors watch the Sionna Therapeutics (SION) presentation on January 13, 2026?

A live webcast will be available on the Investors > Events page at https://investors.sionnatx.com/.

Will a replay of the Sionna (SION) J.P. Morgan presentation be available after the event?

Yes. A replay will be posted on the same Investors > Events page following the presentation.

What is Sionna Therapeutics’ (SION) development focus mentioned for the January 13, 2026 presentation?

The company is a clinical-stage biopharmaceutical developing medicines to normalize CFTR function for cystic fibrosis.

What time should East Coast investors tune in for the Sionna (SION) presentation on January 13, 2026?

East Coast investors should tune in at 12:45 p.m. ET.